血管肉瘤药物治疗进展

doi:10.16352/j.issn.1001-6325.2024.10.1363

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (10): 1363-1367.doi: 10.16352/j.issn.1001-6325.2024.10.1363

血管肉瘤药物治疗进展

葛郁平¹, 刘莹², 赵林^1*

1.中国医学科学院北京协和医学院北京协和医院肿瘤内科,北京 100730;
2.北京朝阳中西医结合急诊抢救医院肿瘤科三区,北京 100122

收稿日期:2024-07-01 修回日期:2024-07-22 出版日期:2024-10-05 发布日期:2024-09-27
通讯作者: ^* wz20010727@aliyun.com
基金资助:
北京协和医院中央高水平医院临床科研专项重大攻关计划(2022-PUMCH-D-002)

Advances in pharmacotherapy for angiosarcoma

GE Yuping¹, LIU Ying², ZHAO Lin^1*

1. Department of Oncology, Peking Union Medical College Hospital,CAMS & PUMC, Beijing 100730;
2. the Third Ward, Department of Oncology,Beijing Chaoyang Integrative Medicine Rescue and First Aid Hospital, Beijing 100122, China

Received:2024-07-01 Revised:2024-07-22 Online:2024-10-05 Published:2024-09-27
Contact: ^* wz20010727@aliyun.com

摘要/Abstract

摘要： 血管肉瘤是起源于血管或淋巴管内皮细胞的罕见的软组织肿瘤,占软组织肉瘤的比例＜1%,多见于皮肤和表面软组织。血管肉瘤诊断依靠病理,免疫组化常见CD31、ERG、CD34表达阳性,临床分期多按照美国癌症联合委员会(AJCC)软组织肉瘤标准。治疗上,根治性手术是局限性血管肉瘤的首选治疗方法;对于不可切除或转移性血管肉瘤,化疗是主要治疗方法,靶向和免疫治疗近年发展迅速,多种药物联合治疗成为未来热点。

关键词: 血管肉瘤, 化疗, 靶向治疗, 免疫治疗

Abstract: Angiosarcoma (AS) is a rare soft tissue sarcoma originating from vascular or lymphatic endothelial cells, accounting for less than 1% of soft tissue sarcomas. It is most common in skin and surface of soft tissue. The diagnosis of AS is based on pathology, and the expression of CD31, ERG and CD34 is commonly positive in immuno-histochemistry. Staging is performed according to the American Joint Committee on Cancer (AJCC)criteria for soft tissue sarcoma. Radical surgery is the primary therapy for locally confined disease. For un-resectable or metastatic angiosarcoma, chemotherapy is the main treatment method. Targeted therapy and immunotherapy have developed rapidly in recent years, and the combined therapy of different types of chemotherapy drug has been the focus of optimization in the future.

Key words: angiosarcoma, chemotherapy, targeted therapy, immunotherapy

中图分类号:

R738.6

葛郁平, 刘莹, 赵林. 血管肉瘤药物治疗进展[J]. 基础医学与临床, 2024, 44(10): 1363-1367.

参考文献

[1]Lara-Martinez H, Weinberg M, Baratam P,et al. Angiosarcoma of the face: a case study and literature review of local and metastatic angiosarcoma[J]. Case Rep Oncol Med, 2021, 2021: 8823585. doi: 10.1155/2021/8823585.
[2]Young RJ, Natukunda A, Litière S, et al. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials[J]. Eur J Cancer, 2014, 50: 3178-3186.
[3]Verweij J, Lee SM, Ruka W, et al. Randomized phase Ⅱ study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group[J]. J Clin Oncol, 2000, 18: 2081-2086.
[4]D′Angelo SP, Munhoz RR, Kuk D, et al. Outcomes of systemic therapy for patients with metastatic angiosarcoma[J]. Oncology, 2015, 89: 205-214.
[5]Schlemmer M, Reichardt P, Verweij J, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group[J]. Eur J Cancer, 2008, 44: 2433-2436.
[6]Penel N, Bui BN, Bay JO, et al. Phase Ⅱ trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study[J]. J Clin Oncol, 2008, 26: 5269-5274.
[7]Yonekura S, Endo Y, Fujii H, et al. Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy[J]. J Dermatol, 2023, 50: 1493-1496.
[8]Stacchiotti S, Palassini E, Sanfilippo R, et al. Gemci-tabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network[J]. Ann Oncol, 2012, 23: 501-508.
[9]Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase Ⅱ study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas[J]. Ann Oncol, 2013, 24: 257-263.
[10]Ray-Coquard IL, Domont J, Tresch-Bruneel E, et al. Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase Ⅱ trial[J]. J Clin Oncol, 2015, 33: 2797-2802.
[11]Yoo C, Kim JE, Yoon SK, et al. Angiosarcoma of the retroperitoneum: report on a patient treated with sunitinib[J]. Sarcoma, 2009, 2009: 360875. doi: 10.1155/2009/360875.
[12]Maki RG, D′Adamo DR, Keohan ML, et al. Phase Ⅱ study of sorafenib in patients with metastatic or recurrent sarcomas[J]. J Clin Oncol, 2009, 27: 3133-3140.
[13]Eberst L, Cropet C, Le Cesne A, et al. The off-label use of targeted therapies in sarcomas: the OUTC′S program[J]. BMC Cancer, 2014, 14: 870.doi: 10.1186/1471-2407-14-870.
[14]Ray-Coquard I, Italiano A, Bompas E, et al. Sorafenib for patients with advanced angiosarcoma: a phase Ⅱ Trial from the French Sarcoma Group (GSF/GETO)[J]. Oncologist, 2012, 17: 260-266.
[15]Xu B, Pan Q, Pan H, et al. Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial[J]. eClinicalMedicine, 2023, 64: 102240.doi:10.1016/j.eclinm.2023.102240.
[16]Gu Y, Meng J, Ju Y, et al. Case report:unique FLT4 variants associated with differential response to anlotinib in angiosarcoma[J]. Front Oncol, 2022, 12: 1027696.doi:10.3389/fonc.2022.1027696.
[17]Ogata D, Yanagisawa H, Suzuki K, et al. Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma[J]. Med Oncol, 201,33: 116.doi:10.1007/s12032-016-0831-z.
[18]Liu M, Liu Y, Guo H, et al. Apatinib, combined with chemotherapy or alone is effective in treating angio-sarcoma: a case report[J]. Anticancer Drugs, 2019,30: e0738. doi: 10.1097/CAD.0000000000000738.
[19]Pasquier E, André N, Street J, et al. Effective management of advanced angiosarcoma by the synergistic combination of propranolol and vinblastine-based metronomic chemotherapy: a bench to bedside study[J]. EBioMedicine, 2016, 6: 87-95.
[20]Schlein LJ, Brill SA, Brady RV, et al. Parthenolide as a therapeutic for disseminated canine neoplasms[J]. J Pharmacol Exp Ther,2024, 388: 774-787.
[21]Mendiola M, Saarela J, Escudero FJ, et al. Characterisation of new in vitro models and identification of potentially active drugs in angiosarcoma[J]. Biomed Pharmacother, 2024, 173: 116397. doi: 10.1016/j.biopha.2024.116397.
[22]Rosenbaum E, Antonescu CR, Smith S, et al. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center[J]. J Immunother Cancer, 2022,10:e004149. doi: 10.1136/jitc-2021-004149.
[23]Florou V, Rosenberg AE, Wieder E, et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution[J]. J Immunother Cancer, 2019, 7: 213. doi: 10.1186/s40425-019-0689-7.
[24]Painter CA, Jain E, Tomson BN, et al. The Angio-sarcoma Project: enabling genomic and clinical disco-veries in a rare cancer through patient-partnered research[J]. Nat Med,2020,26: 181-187.
[25]Wagner MJ, Othus M, Patel SP, et al. Multicenter phase Ⅱ trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)[J]. J Immunother Cancer, 2021, 9:e002990.doi: 10.1136/jitc-2021-002990.

血管肉瘤药物治疗进展

Advances in pharmacotherapy for angiosarcoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	高艺丹, 蒋雪涵, 张红, 杨沛然. 靶向异常通路的动脉性肺动脉高压新型药物研发[J]. 基础医学与临床, 2024, 44(8): 1088-1093.
[2]	张伟, 张振, 刘冬, 江后洲, 梁伟. IMRT联合不同化疗方案在早期食管鳞癌患者中不良反应及疗效的比较[J]. 基础医学与临床, 2024, 44(7): 1018-1022.
[3]	段然, 李青原, 冯同. 代谢重编程在特发性肺纤维化发病中的作用[J]. 基础医学与临床, 2024, 44(6): 882-886.
[4]	李娟, 李晓峰, 徐生志, 唐凯. 华蟾素胶囊联合多西紫杉醇+顺铂化疗用于非小细胞肺癌患者的疗效[J]. 基础医学与临床, 2024, 44(2): 247-251.
[5]	刘宛榕, 赵林. 颅内生殖细胞肿瘤的药物治疗[J]. 基础医学与临床, 2024, 44(10): 1350-1356.
[6]	杨俊豪, 赵林. 恶性间皮瘤的靶向与免疫治疗[J]. 基础医学与临床, 2024, 44(10): 1342-1349.
[7]	张伟, 张振, 杨连任, 梁伟. 肺癌7项抗体水平与NSCLC患者化疗效果及预后的关系[J]. 基础医学与临床, 2024, 44(10): 1383-1387.
[8]	周昕羽, 汤继宏, 肖潇, 冯隽, 杨乐天, 徐欢, 武银银. 儿童急性B淋巴细胞白血病合并化疗诱导周围神经病变的临床特点及预后分析[J]. 基础医学与临床, 2024, 44(10): 1394-1399.
[9]	颜晨红, 金儿. 外泌体PD-L1在非小细胞肺癌诊断和治疗上的研究进展[J]. 基础医学与临床, 2023, 43(9): 1457-1461.
[10]	代娣, 刘玉琴. 原发性胃淋巴瘤的诊断难点及治疗进展[J]. 基础医学与临床, 2023, 43(9): 1462-1466.
[11]	伍琦, 王绍波. CRISPR/Cas9技术在CAR-T细胞治疗肿瘤中作用的研究进展[J]. 基础医学与临床, 2023, 43(8): 1313-1316.
[12]	陈忠婕, 黄嘉如, 胡清, 赵珍琴, 陈俏俏, 孙浚源, 贾静. 免疫检查点CD276蛋白参与肿瘤发生发展作用机制的研究进展[J]. 基础医学与临床, 2023, 43(7): 1143-1147.
[13]	李珍, 段昭君, 罗云萍. 神经节苷脂GD2可作为肺癌干细胞一个潜在的候选标志物[J]. 基础医学与临床, 2023, 43(5): 777-784.
[14]	谭树芬, 杨谢兰, 杨琳琳, 李树清. 紫杉醇联合卡铂化疗对卵巢癌VEGF及肿瘤标志物表达的影响[J]. 基础医学与临床, 2023, 43(12): 1861-1865.
[15]	何丹, 阮中宝. 细胞外囊泡在心房颤动发病中的作用[J]. 基础医学与临床, 2022, 42(4): 671-674.